

\*林樹福醫師

所有發表期刊論文及專書

論文:

1. **Lin SF**, Lin JD, Huang YY. Diabetic ketoacidosis: comparisons of patient characteristics, clinical presentations and outcomes today and 20 years ago. *Chang Gung Med J* 2005;28:24-30.
2. Huang YY, **Lin SF (Corresponding author)**, Dunn P, Wai YY, Hsueh C, Tsai JS. Primary pituitary lymphoma presenting as hypophysitis. *Endocr J* 2005;52:543-9.
3. Huang YY, Yu Z, **Lin SF**, Li S, Fong F, Wong RJ. Nectin-1 Is a Marker of Thyroid Cancer Sensitivity to Herpes Oncolytic Therapy. *J Clin Endocrinol Metab* 2007;92:1965-70.
4. **Lin SF**, Yu Z, Riedl C, Woo Y, Zhang Q, Yu YA, Timiryasova T, Chen N, Shah JP, Szalay AA, Fong Y, Wong RJ. Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. *Surgery* 2007;142:976-83.
5. **Lin SF**, Gao SP, Price D, Li S, Chou TC, Singh P, Huang YY, Fong Y, Wong RJ. Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer. *Clin Cancer Res* 2008;14:1959-28.
6. Yu Z, Li S, Huang YY, **Lin SF**, Fong Y, Wong RJ. Sensitivity of Squamous Cell Carcinoma Lymph Node Metastases to Herpes Oncolytic Therapy. *Clin Cancer Res* 2008;14:1897-1904.
7. Kelly KJ, Woo Y, Brader P, Yu Z, Riedl C, **Lin SF**, Chen N, Yu YA, Rusch VW, Szalay AA, Fong Y. Novel Oncolytic Agent GLV-1h68 Is Effective Against Malignant Pleural Mesothelioma. *Hum Gene Ther* 2008; 19:774-782.
8. **Lin SF**, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA, Chen N, Szalay AA, Fong Y, Wong RJ. Oncolytic Vaccinia Virotherapy of Anaplastic Thyroid Cancer In Vivo. *J Clin Endocrinol Metab*; 2008;93:4403-7.
9. Price DL, **Lin SF**, Han Z, Simpson G, Coffin RS, Wong J, Li S, Fong Y, Wong RJ. Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg*. 2010;136:151-8.
10. Dai MH, Zamarin D, Gao SP, Chou TC, Gonzalez L, **Lin SF**, Fong Y. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. *Br J Surg*. 2010;97:1385-94.
11. Tsai SS, Huang JC, Chen ST, Sun JH, Wang CC, **Lin SF**, Hsu BR, Lin JD, Huang SY, Huang YY. Characteristics of *Klebsiella pneumoniae* bacteremia in community-acquired

and nosocomial infections in diabetic patients. *Chang Gung Med J*. 2010;33:532-9.

12. Huang CH, Chao TC, Hseuh C, Lin KJ, Ho TY, **Lin SF**, Lin JD. Therapeutic outcome and prognosis in young patients with papillary and follicular thyroid cancer.

*Pediatr Surg Int*. 2012;28:489-94.

13. **Lin SF**, Huang YY, Lin JD, Chou TC, Hsueh C, Wong RJ. Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy. *PLoS ONE* 2012;7(10):e46726. doi:10.1371/journal.pone.0046726.

14. **Lin SF**, Lin JD, Chou TC, Huang YY, Wong RJ. Utility of a Histone Deacetylase Inhibitor (PXD101) For Thyroid Cancer Treatment. *PLoS ONE* 2013;8(10): e77684. doi:10.1371/journal.pone.0077684.

15. Kuo SF, **Lin SF**, Chao TC, Hsueh C, Lin KJ, Lin JD. Prognosis of Multifocal Papillary Thyroid Carcinoma. *Int J Endocrinol*. 2013;2013:809382. doi: 10.1155/2013/809382.

16. Chen CH, Chen WY, **Lin SF**, Wong RJ. Epithelial mesenchymal transition enhances response to oncolytic herpes viral therapy through nectin-1. *Hum Gene Ther*. 2014 Feb 25. [Epub ahead of print]

#### 專書:

1. Clinical Practice Guideline for Postprandial Hyperglycemia, 1<sup>st</sup> ed (2009). The Diabetes Association of the Republic of China (Taiwan), Taipei, Taiwan (in Chinese)
2. Clinical Practice Guideline for Postprandial Hyperglycemia, 2<sup>nd</sup> ed (2012). The Diabetes Association of the Republic of China (Taiwan), Taipei, Taiwan (in Chinese)